Aegerion Pharmaceuticals Insider Unloads $326,095 in Stock (AEGR)
Aegerion Pharmaceuticals (NASDAQ:AEGR) Insider Mark Sumeray sold 3,500 shares of the company’s stock on the open market in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $93.17, for a total value of $326,095.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on AEGR shares. Analysts at Lazard Capital Markets raised their price target on shares of Aegerion Pharmaceuticals from $86.00 to $105.00 in a research note to investors on Thursday, August 1st. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Aegerion Pharmaceuticals from $82.00 to $92.00 in a research note to investors on Wednesday, July 31st. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday, July 31st. They now have a $85.00 price target on the stock, down previously from $107.00. Nine research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $82.96.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 7.98% during mid-day trading on Tuesday, hitting $84.98. 817,733 shares of the company’s stock traded hands. Aegerion Pharmaceuticals has a 1-year low of $13.50 and a 1-year high of $99.00. The stock’s 50-day moving average is $89.00 and its 200-day moving average is $68.74. The company’s market cap is $2.462 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Tuesday, July 30th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.04. The company had revenue of $6.50 million for the quarter, compared to the consensus estimate of $4.27 million. Analysts expect that Aegerion Pharmaceuticals will post $-2.16 EPS for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.